On October 2, the Company announced retirement of a $160,000 note.
The $212,959 and $250,000 notes were signed in 2007 with CorCell, Inc., which became Cord Blood America's operating unit, CorCell Companies, Inc., and were purchased by JMJ Financial. The $285,000 note was originally signed in August 2006 with Strategic Working Capital and subsequently purchased by JMJ Financial. All three notes were retired by September 30, 2009.
"A major effort has been made this year to reduce debt and strengthen our balance sheet for our future and our shareholders' future. We are proud of these accomplishments," said Matthew Schissler, co-founder and CEO.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI | Quote | Chart | News | PowerRating) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
http://www.cordblood-america.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index